Lemborexant

• Insomnia
• Sleep Onset Difficulties
• Sleep Maintenance Problems
• Sleep Disorders

Lemborexant, marketed as Dayvigo, is a dual orexin receptor antagonist (DORA) approved by the FDA in late 2019 for adults with insomnia characterized by sleep-onset and/or sleep-maintenance difficulties. It belongs to a small but growing class of sleep medications that quiet the brain's wakefulness signal rather than amplifying inhibitory GABA tone, and that mechanistic difference matters: orexin antagonism produces sleep that more closely resembles natural sleep architecture and tends to carry a lower burden of next-day sedation, cognitive blunting, and dependence than older hypnotics. For patients who have struggled with benzodiazepine-receptor agonists like zolpidem or eszopiclone — whether because of tolerance, complex sleep behaviors, or cognitive side effects — lemborexant offers a meaningful alternative.

Mechanism of Action

Orexins (also called hypocretins) are two related neuropeptides — orexin A and orexin B — produced by a small cluster of neurons in the lateral and posterior hypothalamus. They are released onto wake-promoting nuclei throughout the brain stem and forebrain, including the locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), dorsal raphe (serotonin), and ventral tegmental area (dopamine). Binding to OX1R and OX2R receptors stimulates these arousal centers and stabilizes wakefulness. The discovery that loss of orexin neurons causes narcolepsy with cataplexy in humans confirmed that this system is essentially the master switch for staying awake.

Lemborexant competitively antagonizes both OX1R and OX2R with similar affinity. By blocking orexin signaling at bedtime, it lowers the wake-promoting drive and allows the homeostatic and circadian sleep pressure that has accumulated through the day to take over. Importantly, this mechanism does not directly suppress respiration or impair muscle tone the way benzodiazepine agonists can, and it preserves more REM and slow-wave sleep architecture than older hypnotics. The half-life is roughly 17 to 19 hours at the 5 mg dose and somewhat longer at 10 mg, which can produce next-morning residual effect in sensitive patients. For more on the broader sleep-wake biology, our neurologic specialty page provides additional context.

Clinical Use

Lemborexant is approved for adult insomnia involving sleep-onset latency, sleep maintenance, or both. The two pivotal phase 3 trials (SUNRISE-1 and SUNRISE-2) demonstrated improvements in subjective and polysomnographic sleep onset, wake after sleep onset, and total sleep time versus placebo and, in SUNRISE-1, versus zolpidem extended-release in older adults. Effects were sustained through at least 12 months of nightly dosing, with no signal of rebound insomnia upon discontinuation. Clinically, DORAs are increasingly favored over benzodiazepines and Z-drugs in older adults, in patients with prior complex sleep behaviors, and in those with comorbid mild cognitive impairment, because the cognitive and falls-risk profile appears more favorable. The American Academy of Sleep Medicine's most recent insomnia guideline includes DORAs as a recommended option. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per AASM recommendations, and lemborexant is generally considered when CBT-I is unavailable, declined, or insufficient. For patients seeking non-pharmacologic strategies first, our sleep hygiene better rest guide reviews behavioral foundations and our screen time impact on sleep quality article addresses an often-overlooked contributor to chronic insomnia.

How to Take It

The starting dose is 5 mg taken immediately before bedtime with at least seven hours remaining before the planned wake time. Based on response and tolerability, the dose may be increased to a maximum of 10 mg nightly. Lemborexant should not be taken with or shortly after a meal — high-fat meals delay onset, blunt peak concentration, and may dull the medication's sleep-onset effect. The tablet is swallowed whole with water; it should not be split, chewed, or crushed because it has not been studied that way. If a patient wakes during the night and has fewer than seven hours before they need to be alert, they should not take an additional dose. Unlike some hypnotics, lemborexant can be used nightly without strict short-term limits, although the long-term need should be reassessed periodically. Most patients notice improved sleep onset within the first one to three nights, with maximum maintenance benefits emerging over one to two weeks. Storage is room temperature in the original blister pack. Alcohol potentiates CNS depressant effects and should be avoided.

Monitoring and Follow-Up

No specific laboratory monitoring is required. Clinical reassessment at two weeks, six weeks, and three months is reasonable to verify continued benefit, screen for residual morning sedation, and detect emerging parasomnias such as sleep-walking, sleep-driving, or sleep-eating. Patients should be asked specifically about morning grogginess, dream content, sleep paralysis, and hallucinations on falling asleep or waking, since these orexin-related phenomena can occur. Because depression sometimes presents with insomnia, clinicians should monitor mood and screen for suicidal ideation periodically, and document any worsening. Falls risk should be assessed, especially in older adults — patients waking at night should sit at the bedside briefly before standing. Driving performance the morning after should be reviewed, particularly at the 10 mg dose, where impairment may persist. Reviewing this medication at your annual physical visit is a natural time to revisit ongoing sleep medication need.

Special Populations

In elderly patients, no formal dose change is mandated, but lower doses (5 mg) are generally preferred because of slower clearance and increased fall risk. No renal dose adjustment is required for any degree of renal impairment, including end-stage disease. In moderate hepatic impairment (Child-Pugh B), the maximum dose is 5 mg; severe hepatic impairment is not recommended because exposure rises substantially. Pregnancy data are limited; animal studies showed embryo-fetal effects only at exposures well above human therapeutic doses, but lemborexant should be used in pregnancy only if clearly needed. Lactation data are absent — exposure through milk is theoretically possible given the lipophilicity. Pediatric safety has not been established and use in patients under 18 is not recommended. Patients with narcolepsy or other primary hypersomnias should not use lemborexant, as it could exacerbate underlying orexin deficiency. Patients with severe sleep apnea were excluded from trials, and the medication should be used cautiously in untreated obstructive sleep apnea or COPD because of theoretical respiratory concerns.

When to Contact Your Doctor

Report any sleep-walking, sleep-driving, eating or making phone calls without memory of the event, or any behavior during sleep that worries family members — these complex sleep behaviors warrant immediate discontinuation. Daytime episodes of muscle weakness or sudden loss of muscle tone resembling cataplexy, persistent next-day sedation interfering with driving, new or worsening depression, or any thoughts of self-harm need urgent evaluation. Worsening insomnia despite adherence, sleep paralysis that becomes disruptive, or vivid hallucinations on falling asleep or waking should be reported. Patients combining lemborexant with opioids, benzodiazepines, or alcohol should be aware of additive respiratory and cognitive effects. The FDA Dayvigo label and MedlinePlus lemborexant page provide additional consumer resources.

Practical Tips for Daily Use

Lemborexant works best when paired with a stable bedtime routine. The medication is most effective when taken on an empty stomach roughly 30 minutes before lying down — eating immediately before the dose will delay onset and may produce a frustrating night. Avoid alcohol within several hours of bedtime; it potentiates next-morning sedation and degrades sleep quality. Keep the bedroom cool, dark, and free of screens; the most common reason patients perceive lemborexant as ineffective is environmental disruption (a phone glowing on the nightstand, a hot bedroom, irregular bedtimes). If you wake during the night, do not take an additional dose, even at the 5 mg strength — the long half-life means a second dose substantially raises next-morning impairment. Do not drive or operate heavy machinery within 9 hours of taking the medication; this is particularly important during the first week and at the 10 mg dose. If you find that you regularly need more than 7 hours in bed to feel rested, that is normal physiology; many adults need 7 to 9 hours. Reassess the need for chronic sleep medication every few months — many patients find that addressing underlying contributors (caffeine timing, stress, untreated sleep apnea) eventually allows the medication to be tapered.

Working With Your Care Team

Insomnia is rarely just about a pill — addressing sleep hygiene, screening for depression and obstructive sleep apnea, and trying CBT-I are essential parts of the picture. Schedule a visit with our team to discuss whether lemborexant fits within a comprehensive sleep plan tailored to your circumstances.